The associations of oxaliplatin-induced peripheral neuropathy, sociodemographic characteristics, and clinical characteristics with time to fall in older adults with colorectal cancer

被引:2
|
作者
Hines, Robert B. [1 ]
Schoborg, Christopher [2 ]
Sumner, Timothy [2 ]
Thiesfeldt, Dana-Leigh [3 ]
Zhang, Shunpu [2 ]
机构
[1] Univ Cent Florida, Coll Med, Dept Populat Hlth Sci, 900 Lake NonaBlvd, Orlando, FL 32827 USA
[2] Univ Cent Florida, Coll Sci, Dept Stat & Data Sci, Orlando, FL 32827 USA
[3] Univ Cent Florida, Coll Med, Dept Med Educ, Orlando, FL 32827 USA
关键词
colorectal cancer; chemotherapy-induced peripheral neuropathy; oxaliplatin; falls; QUALITY-OF-LIFE; RISK-FACTORS; ADJUVANT TREATMENT; CHEMOTHERAPY; HEALTH; INJURIES; CIRRHOSIS; FRAILTY; PEOPLE; CLAIMS;
D O I
10.1093/aje/kwae067
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Our purpose was to investigate the associations between falls and oxaliplatin-induced peripheral neuropathy (OIPN), sociodemographic characteristics, and clinical characteristics of older patients with colorectal cancer. The study population consisted of older adults diagnosed with colorectal cancer whose data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. We defined OIPN using specific (OIPN 1) and broader (OIPN 2) definitions of OIPN, based on diagnosis codes. Extensions of the Cox regression model to accommodate repeated events were used to obtain overall hazard ratios (HRs) with 95% CIs and the cumulative hazard of fall. The unadjusted risk of fall for colorectal cancer survivors with versus without OIPN 1 at 36 months of follow-up was 19.6% versus 14.3%, respectively. The association of OIPN with time to fall was moderate (for OIPN 1, HR = 1.37; 95% CI, 1.04-1.79) to small (for OIPN 2, HR = 1.24; 95% CI, 1.01-1.53). Memantine, opioids, cannabinoids, prior history of fall, female sex, advanced age and disease stage, chronic liver disease, diabetes, and chronic obstructive pulmonary disease all increased the hazard rate of falling. Incorporating fall prevention in cancer care is essential to minimize morbidity and mortality of this serious event in older survivors of colorectal cancer.
引用
收藏
页码:1271 / 1280
页数:10
相关论文
共 50 条
  • [31] Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients
    Makoto Nagashima
    Mitsuru Ooshiro
    Ayako Moriyama
    Yui Sugishita
    Kengo Kadoya
    Ayami Sato
    Tomoaki Kitahara
    Ryuichi Takagi
    Tasuku Urita
    Yutaka Yoshida
    Hiroshi Tanaka
    Takashi Oshiro
    Shinichi Okazumi
    Ryoji Katoh
    Supportive Care in Cancer, 2014, 22 : 1579 - 1584
  • [32] Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies
    Cheng, Fang
    Zhang, Ruoqi
    Sun, Chen
    Ran, Qian
    Zhang, Cuihan
    Shen, Changhong
    Yao, Ziqing
    Wang, Miao
    Song, Lin
    Peng, Cheng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [33] Clinical efficacy of compression therapy in preventing oxaliplatin-induced peripheral neuropathy: a prospective, randomized controlled study
    Xiaotao Zhang
    Le Yu
    Yueyue Guo
    Jie Su
    Yang Yang
    Jiawei Li
    Weizhong Li
    Zhiling Sun
    Supportive Care in Cancer, 2025, 33 (6)
  • [34] Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
    Velasco, Roser
    Bruna, Jordi
    Briani, Chiara
    Argyriou, Andreas A.
    Cavaletti, Guido
    Alberti, Paola
    Frigeni, Barbara
    Cacciavillani, Mario
    Lonardi, Sara
    Cortinovis, Diego
    Cazzaniga, Marina
    Santos, Cristina
    Kalofonos, Haralabos P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (04) : 392 - 398
  • [35] Oxaliplatin-Induced Neuropathy in Colorectal Cancer: Many Questions With Few Answers
    Zedan, Ahmed Hussein
    Hansen, Torben Frostrup
    Svenningsen, Asa Fex
    Vilholm, Ole Jakob
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 73 - 80
  • [36] Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer
    Jung, Hye Jeong
    Ahn, Soo Jung
    Yang, Yoo Ri
    Kim, Kyoung A.
    Shin, Sang Joon
    Jung, Min Kyu
    Chu, Sang Hui
    ASIAN ONCOLOGY NURSING, 2019, 19 (04) : 204 - 213
  • [37] Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study
    Kazuaki Okamoto
    Hiroaki Nozawa
    Shigenobu Emoto
    Koji Murono
    Kazuhito Sasaki
    Soichiro Ishihara
    Supportive Care in Cancer, 2023, 31
  • [38] Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Bruno Vincenzi
    Anna Maria Frezza
    Gaia Schiavon
    Chiara Spoto
    Raffaele Addeo
    Vincenzo Catalano
    Francesco Graziano
    Daniele Santini
    Giuseppe Tonini
    Supportive Care in Cancer, 2013, 21 : 1313 - 1319
  • [39] Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Vincenzi, Bruno
    Frezza, Anna Maria
    Schiavon, Gaia
    Spoto, Chiara
    Addeo, Raffaele
    Catalano, Vincenzo
    Graziano, Francesco
    Santini, Daniele
    Tonini, Giuseppe
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1313 - 1319
  • [40] Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development
    Yang, Yang
    Zhao, Bing
    Gao, Xuejiao
    Sun, Jinbing
    Ye, Juan
    Li, Jun
    Cao, Peng
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)